Fusion protein

Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Neurodegeneration, Cancer, Biomarker, Private Securities Litigation Reform Act, ALEC, Investor, Society for Immunotherapy of Cancer, Clinical trial, Alector, Myelocyte, Immune system, Disease, Security (finance), Society, Research, Frontotemporal dementia, Repolarization, Lists of diseases, Fusion protein, Neoplasm, Annual general meeting, U.S. Securities and Exchange Commission, GLOBE, SEC, Mouse, Immunotherapy, Poster, Drug, Vaccine, Pharmaceutical industry

WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented preclinical data from its AL009 immuno-oncology program in poster at the Society for Immunotherapy of Cancer’s 36th Annual Meeting.

Key Points: 
  • AL009 Targets Innate Immune Checkpoint Receptors, Blocks Immune Suppression of Tumor Cells and Activates Potent Anti-Cancer Immune Response
    WASHINGTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented preclinical data from its AL009 immuno-oncology program in poster at the Society for Immunotherapy of Cancers 36th Annual Meeting.
  • AL009 acts as a checkpoint inhibitor, blocking the immunosuppressive effect of multiple Siglecs and thereby enhancing both the innate and adaptive immune system response to cancer.
  • Alector is developing AL009 for the potential treatment of solid tumor cancers and plans to initiate a first-in-human clinical trial of AL009 in 2022.
  • Alector is initially developing AL009 for the potential treatment of solid tumors, with plans to initiate first-in-human clinical studies in 2022.

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting

Retrieved on: 
Wednesday, November 3, 2021
Annual general meeting, Clinical trial, SAN, Alzheimer's disease, Cancer, Neurodegeneration, Fusion protein, Immunotherapy, Walter, Alector, Society, Frontotemporal dementia, Repolarization, Review, ID, Conference, AbbVie, Lists of diseases, Webcast, Biomarker, Immune system, GLOBE, Immunology, SITC, ALEC, Communications satellite, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 9-12, 2021 virtually and in Boston, and the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting held November 12-14, 2021 virtually and in Washington, D.C.

Key Points: 
  • Among the data being presented at CTAD are twelve-month biomarker and clinical data from the open-label Phase 2 INFRONT-2 study evaluating AL001 in individuals with frontotemporal dementia due to progranulin gene mutation (FTD-GRN).
  • Alector will also present data from its Phase 1 study of AL003 in healthy volunteers and participants with Alzheimers disease.
  • At SITC, Alector will provide an update on AL009, a first-in-class multi-Siglec inhibitor that enhances innate and adaptive immunity to cancer by blocking a critical glycan checkpoint pathway.
  • Alector plans to host a conference call to review these data and the progress across its pipeline on November 12, 2021, at 4:00 p.m.

LSBio Acquires Absolute Antibody Ltd.

Retrieved on: 
Tuesday, December 22, 2020
Medical Supplies, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Proteins, Biology, Immunology, Antibodies, Glycoproteins, Recombinant antibodies, Fusion protein, Antibody Solutions, Genetex

LSBio (LSBio), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast.

Key Points: 
  • LSBio (LSBio), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast.
  • Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats.
  • We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies, said Dr. Heather Holemon, CEO of LSBio.
  • We are delighted to be joining forces with the LSBio team, said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody.

Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review

Retrieved on: 
Monday, December 21, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cancer, Fusion protein, Bladder cancer, Urinary bladder, Vicineum™, Non-Muscle Invasive Bladder Cancer, Sesen Bio

We look forward to continuing our regulatory progress by submitting a Marketing Authorization Application in Europe, which we anticipate in early 2021.

Key Points: 
  • We look forward to continuing our regulatory progress by submitting a Marketing Authorization Application in Europe, which we anticipate in early 2021.
  • Vicineum, a locally administered fusion protein, is Sesen Bios lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
  • Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement

Retrieved on: 
Thursday, December 17, 2020
Branches of biology, Biology, Biotechnology, Fusion protein, Life sciences, Polyclonal antibodies

This is the first license under a multi-product development agreement between Inhibrx and Arecor.

Key Points: 
  • This is the first license under a multi-product development agreement between Inhibrx and Arecor.
  • Arestat is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of therapeutic proteins and peptides.
  • This collaboration demonstrates the unique capability of the Arestat technology to deliver superior reformulations of complex fusion proteins in this case for treatment of an orphan disease.
  • Terms and conditions relating to the use and distribution of this information may apply.

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

Retrieved on: 
Tuesday, December 1, 2020
Life sciences, Biology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Pharming, Vaccine, Fusion protein, Biotechnology

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract development and manufacturing organization (CDMO), today announced that it has entered into its first Statement of Work (SoW) under a Master Services Agreement with Belgium-based ATB Therapeutics (atbtherapeutics) to produce its bioengineered antibody-toxin fusion proteins using iBios FastPharming System.

Key Points: 
  • BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract development and manufacturing organization (CDMO), today announced that it has entered into its first Statement of Work (SoW) under a Master Services Agreement with Belgium-based ATB Therapeutics (atbtherapeutics) to produce its bioengineered antibody-toxin fusion proteins using iBios FastPharming System.
  • The fusion proteins, called atbodies, are being designed for the treatment of cancers.
  • The atb ody is a novel therapeutic that can only be achieved using atbtherapeutics proprietary plant-based atb iofarm technology.
  • Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases.

Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2

Retrieved on: 
Wednesday, July 1, 2020
Branches of biology, Medical specialties, Glycoproteins, Proteins, Immunology, Vaccination, Severe acute respiratory syndrome-related coronavirus, Fusion protein, Immunoglobulin G, Antibody, Vaccine, Protein A/G

T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.

Key Points: 
  • T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.
  • Novel protein to progress as priority vaccine candidate development program.
  • T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc).
  • Immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration.

GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals

Retrieved on: 
Monday, June 8, 2020
Professional services, Health, Finance, Banking, Pharmaceutical, Biotechnology, Articles, Business, Life sciences, Biopharmaceutical, Biotechnology, Pharmaceutical industry, Pharmacy, Fusion protein, Trimer, Hillhouse Capital Group, Entrepreneurship, Clover Biopharmaceuticals, GL Ventures

Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24 million Series B-2 financing from GL Ventures.

Key Points: 
  • Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced the completion of a US$ 24 million Series B-2 financing from GL Ventures.
  • Clover Biopharmaceuticals is the innovator of Trimer-Tag, an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
  • The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time.
  • GL Ventures is the early stage affiliate of Hillhouse Capital and has been investing with innovators across the world since 2005.

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

Retrieved on: 
Tuesday, March 24, 2020
Medical specialties, Branches of biology, Medicine, Immunology, Biotechnology, Immune system, Monoclonal antibody, Antibody, Fusion protein, Severe acute respiratory syndrome-related coronavirus, Epitope, Proteins

Mabpharm has generated a fusion protein (CMAB020) that binds to the spike protein of the SARS-CoV-2 virus.

Key Points: 
  • Mabpharm has generated a fusion protein (CMAB020) that binds to the spike protein of the SARS-CoV-2 virus.
  • The other arm (TR) is a truncated ACE2 protein that binds to a different epitope of the spike protein.
  • The ACE-MAB fusion protein could also block the receptor binding domain (RBD) with CD147 to mitigate lung inflammation and cytokine storm.
  • Mabpharm has strong internal research, preclinical and clinical development capabilities, with a special focus on the development and manufacturing of monoclonal antibodies.

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®

Retrieved on: 
Tuesday, February 25, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, RTT, Cancer, Bladder cancer, Fusion protein, Health

ET to provide an overview of 2019 operational performance and key updates on the Companys regulatory progress and commercial opportunity for Vicinium.

Key Points: 
  • ET to provide an overview of 2019 operational performance and key updates on the Companys regulatory progress and commercial opportunity for Vicinium.
  • To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to conference ID 1497176.
  • Vicinium, a locally administered fusion protein, is Sesen Bios lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.